Results 1 to 10 of about 469,365 (378)

PaR1 secreted by the type IX secretion system is a protective antigen of Riemerella anatipestifer [PDF]

open access: yesFrontiers in Microbiology, 2023
Riemerella anatipestifer mainly infects domestic ducks, geese, turkeys, and other birds, and causes considerable economic losses to the global duck industry. Previous studies have shown that concentrated cell-free culture filtrates of R.
Jialing Wang   +7 more
doaj   +2 more sources

Recombinant full-length Bacillus Anthracis protective antigen and its 63 kDa form elicits protective response in formulation with addavax [PDF]

open access: yesFrontiers in Immunology, 2023
IntroductionBacillus anthracis is the causative agent for the lethal disease anthrax, primarily affecting animals and humans in close contact with an infected host. The pathogenicity of B. anthracis is attributed to the secreted exotoxins and their outer
Shikhar Sharma   +6 more
doaj   +2 more sources

A STUDY ON THE PROTECTIVE ANTIGEN OF PSEUDOMONAS AERUGINOSA

open access: bronzeNippon Jibiinkoka Gakkai Kaiho, 1966
It has been generally accepted that Pseudo- monas aeruginosa is one of the organisms most resistant to antibiotics. In the present study, Pseudomonas aeruginosa strain A3 was pursued in mice revealing its protective antigen localed in its cell wall. Preparation of cell walls during the present experiments was performed with mechanical des- truction and
Masao Sugiyama
openalex   +5 more sources

Impact of HLA Polymorphism on the Immune Response to Bacillus Anthracis Protective Antigen in Vaccination versus Natural Infection [PDF]

open access: yesVaccines, 2022
The causative agent of anthrax, Bacillus anthracis, evades the host immune response and establishes infection through the production of binary exotoxins composed of Protective Antigen (PA) and one of two subunits, lethal factor (LF) or edema factor (EF).
Stephanie Ascough   +14 more
doaj   +2 more sources

Two approaches for the stabilization of Bacillus anthracis recombinant protective antigen [PDF]

open access: yesHuman Vaccines & Immunotherapeutics, 2021
Anthrax is a zoonotic disease caused by the gram-positive spore-forming bacteria Bacillus anthracis. There is a need for safe, highly effective, long-term storage vaccine formulations for mass vaccination. However, the development of new subunit vaccines
Ekaterina M. Ryabchevskaya   +7 more
doaj   +2 more sources

Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax [PDF]

open access: yesFrontiers in Immunology, 2018
Anthrax is an era old deadly disease against which there are only two currently available licensed vaccines named anthrax vaccine adsorbed and precipitated (AVP).
Anshu Malik   +4 more
doaj   +2 more sources

Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine [PDF]

open access: yesHuman Vaccines & Immunotherapeutics, 2020
Polysaccharides isolated from natural plants may represent a novel source of vaccine adjuvants. In this research, we focused on a natural plant polysaccharide, PCP-I, which is derived from Poria cocos, a Chinese traditional herbal medicine.
Kun Liu   +8 more
doaj   +2 more sources

Role of the Antigen Capture Pathway in the Induction of a Neutralizing Antibody Response to Anthrax Protective Antigen [PDF]

open access: yesmBio, 2018
Toxin neutralizing antibodies represent the major mode of protective immunity against a number of toxin-mediated bacterial diseases, including anthrax; however, the cellular mechanisms that lead to optimal neutralizing antibody responses remain ill ...
Anita Verma   +5 more
doaj   +2 more sources

Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine Delivery [PDF]

open access: yes, 2013
Protein-based vaccine development faces the difficult challenge of finding robust yet non-toxic adjuvants suitable for humans. Here, using a molecular engineering approach, we have developed a molecular platform for generating self-adjuvanting immunogens
A Demissie   +68 more
core   +12 more sources

A Quantum Vaccinomics Approach for the Design and Production of MSP4 Chimeric Antigen for the Control of Anaplasma phagocytophilum Infections

open access: yesVaccines, 2022
Anaplasma phagocytophilum Major surface protein 4 (MSP4) plays a role during infection and multiplication in host neutrophils and tick vector cells. Recently, vaccination trials with the A.
José de la Fuente   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy